Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Regeneron Pharmaceuticals, Inc. News release: Regeneron reports first quarter 2018 financial and operating results. 2018 May 3.
2. Taylor NP. Regeneron halts high doses of phase 3 osteoarthritis drug fasinumab amid risk-benefit concerns. FierceBiotech. 2018 May 3.
3. Stein R. FDA panel affirms safety of painkiller celebrex. NPR. 2018 Apr 25.